Education
About Us
Working with TipRanks
Follow Us
Korro Bio (KRRO)
NASDAQ:KRRO
KRRO Stock Chart & Stats
$10.75
-$1.03(-2.68%)
At close: 4:00 PM EST
$10.75
-$1.03(-2.68%)
Day’s Range― - ―
52-Week Range$5.20 - $55.89
Previous CloseN/A
Volume28.02K
Average Volume (3M)734.66K
Market Cap
$105.00M
Enterprise Value$124.52M
Total Cash (Recent Filing)$93.48M
Total Debt (Recent Filing)$44.67M
Price to Earnings (P/E)―
Beta2.57
Next Earnings
Mar 31, 2026EPS Estimate
-2.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding9,417,295
10 Day Avg. Volume1,808,258
30 Day Avg. Volume734,659
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.12
Price to Sales (P/S)149.54
P/FCF Ratio-4.36
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue16.89
Enterprise Value/Gross Profit16.89
Enterprise Value/Ebitda-1.41
Forecast
1Y Price Target
$21.00Price Target Upside95.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-8.1
Revenue Forecast (FY)$2.20M
Bulls Say, Bears Say
Bulls Say
Analyst RatingAnalyst upgrade to Outperform reflects belief that updated modeling and KRRO-121's development materially improve the stock's risk/reward and could help rebuild investor confidence if clinical readouts are favorable.
Delivery TechnologyShift to GalNAc-conjugated delivery for KRRO-121 targets liver cells directly and is intended to overcome prior delivery shortcomings, increasing the probability of successful translation to humans compared with the earlier lipid nanoparticle approach.
Preclinical Efficacy And SafetyPreclinical data, including studies in non-human primates, showed repeatable reductions in ammonia, liver-selective distribution, minimal off-target exposure, and no meaningful organ safety signals, supporting the rationale for clinical testing.
Bears Say
Clinical Delivery Failure RiskDisappointing interim data from a prior program showed very low levels of corrected protein in patients, indicating a potential delivery failure rather than a flaw in the underlying editing approach and raising concern that delivery issues could recur.
Financing And Regulatory ExecutionLimited cash runway and the need for additional capital create dilution risk, while regulatory authorities may demand demonstration of event or hospitalization reduction beyond biomarker changes, increasing execution and approval uncertainty.
Formulation VariabilityEx‑vivo findings that the lipid nanoparticle structure differs between patients and healthy volunteers suggest formulation or biological variability could undermine clinical exposure and require significant additional development work.
Korro Bio News
KRRO FAQ
What was Korro Bio’s price range in the past 12 months?
Korro Bio lowest stock price was $5.20 and its highest was $55.89 in the past 12 months.
What is Korro Bio’s market cap?
Korro Bio’s market cap is $105.00M.
When is Korro Bio’s upcoming earnings report date?
Korro Bio’s upcoming earnings report date is Mar 31, 2026 which is in 26 days.
How were Korro Bio’s earnings last quarter?
Korro Bio released its earnings results on Nov 12, 2025. The company reported -$1.92 earnings per share for the quarter, beating the consensus estimate of -$2.594 by $0.674.
Is Korro Bio overvalued?
According to Wall Street analysts Korro Bio’s price is currently Undervalued.
Does Korro Bio pay dividends?
Korro Bio does not currently pay dividends.
What is Korro Bio’s EPS estimate?
Korro Bio’s EPS estimate is -2.07.
How many shares outstanding does Korro Bio have?
Korro Bio has 9,417,295 shares outstanding.
What happened to Korro Bio’s price movement after its last earnings report?
Korro Bio reported an EPS of -$1.92 in its last earnings report, beating expectations of -$2.594. Following the earnings report the stock price went down -79.313%.
Which hedge fund is a major shareholder of Korro Bio?
Currently, no hedge funds are holding shares in KRRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Korro Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.00 (95.35% Upside)
$21.00 (95.35% Upside)
Hedge Fund Trend
Decreased
By 681.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-88.72%
12-Months-Change
Fundamentals
Return on Equity
-63.46%
Trailing 12-Months
Asset Growth
-33.67%
Trailing 12-Months
Company Description
Korro Bio
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
KRRO Stock 12 Month Forecast
Average Price Target
$21.00
▲(95.35% Upside)
Technical Analysis
Assembly Biosciences
―
Annexon Biosciences
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Aura Biosciences Inc
―